Menu

Foundation-led Drug Discovery

Virtual biotechs target and develop translational research.

Sep 1, 2008
Robert E. Pacifici and David P. Rankin

Foundations that support efforts to find treatments for rare diseases have stepped in to fill a significant funding gap caused by increasingly conservative venture capitalists and constraints at large pharmaceutical companies. Their considerable financial (in the tens of millions of dollars for many foundations) and intellectual involvement has triggered collaborative translational drug discovery efforts. CHDI Foundation, a virtual biotech exclusively focused on the discovery and development of drugs for Huntington's disease (HD) is one such organization.

Our enterprise is privately funded with a mandate to fast-track possible therapies for HD. Hence, CHDI strives to support all aspects of the drug development process from early exploratory efforts to identify and validate targets, to the screening, medicinal chemistry, preclinical optimization, on through the clinical and regulatory aspects of evaluating candidate molecules in human trials. Without wet-labs and staffed by more than forty individuals who bring a wealth of scientific, medical, business, legal and technical experience, CHDI's virtual model relies on the world-wide orchestration of over 400 full-time equivalent individuals working in academic institutions, contract research organizations, and biotechnology companies.

The challenge we face is to facilitate and expedite the sharing of research tools and results among academic and industrial HD investigators while protecting publication rights and the ownership of intellectual property. Our support to academic researchers is structured similarly to that provided to our corporate partners: through contracts. Investigators provide periodic progress reports that may be shared, in confidence, with other scientists; deliverables include access to any reagents and non-exclusive licenses to any intellectual property (such as assay system protocols) developed under a contract. To encourage research related to HD, all such reagents are quality controlled and made publicly accessible via a centralized repository (http://ccr.coriell.org/Sections/Collections/CHDI/?SsId=45).

University laboratories provide insights which allow us to identify and validate the targets, mechanisms, pathways, and networks that are the most relevant intervention points for HD. Once a target has been selected, we stress early proof-of-concept experiments since, unlike other drug discovery units, our singular focus on HD prevents us from opportunistically moving into alternate indications.

A network of fee-for-service contract research organizations (CROs) provides the brick-and-mortar laboratories and skilled staff to execute CHDI-sponsored drug development activities. In some cases, these efforts may be assembled from individual experiments (formulation, pharmacokinetic studies, blood-brain barrier penetration) at different places; but they also include semi-integrated programs in which iterative cycles of chemical synthesis and biological annotation drive structure-activity-relationships for projects at the lead optimization phase. Other programs, anti-sense against huntingtin for example, are conducted as joint ventures with biotech partners.

Preparation for clinical trials is proceeding along with efforts to develop therapeutics. These studies are an invaluable resource for developing biomarkers and rating scales and, in the near future, for therapeutic trials recruitment. CHDI has provided support for selected interventional trials which, to date, have only tested nutriceuticals or attempted to repurpose existing drugs. Our strong belief is that de novo development of NCEs (new chemical entities) will be necessary for a true disease-modifying therapy for HD. Our great hope is that once we have de-risked candidate HD therapies by demonstrating preliminary efficacy, that they will be attractive in-licensing opportunities for the large pharmaceutical companies who are much better poised to fund and conduct the later stage development activities.

Looking from the industrial and academic edges of the translational research chasm, any effort to build a bridge seemed daunting, but looking up from the basin, we saw an opportunity. Our solution: Provide a scaffold that can adapt to changes in the landscape and incorporate the combined knowledge and strengths of all the parties involved.

Robert E. Pacifici is Chief Scientific Officer and David P. Rankin is Chief Legal Officer of CHDI.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.